Crystalline form, preparation method, and use of 20(S)-protopanaxadiol

Novel crystalline forms of 20(S)-protopanaxadiol with enhanced properties address the limitations of existing products by providing improved bulk density and stability, facilitating their use in pharmaceutical applications for various therapeutic indications.

JP2026537458APending Publication Date: 2026-11-09SHANGHAI BAOCHENG TAILAI TECHNOLOGY CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2026525637
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-10-30
Filing Date
2024-12-20
Publication Date
2026-11-09

AI Technical Summary

Technical Problem

Existing 20(S)-protopanaxadiol products exhibit low bulk density, low solubility, and poor mechanical stability, limiting their effectiveness and applicability in pharmaceutical development.

Method used

Development of novel crystalline forms A and B of 20(S)-protopanaxadiol with specific diffraction peaks and controlled preparation methods using good and poor solvents, temperature cycles, and filtration to achieve high bulk density and stability.

Benefits of technology

The novel crystalline forms exhibit improved bulk density, solubility, and mechanical stability, making them suitable for widespread use in pharmaceutical formulations for antidepressants, anti-anxiety, anti-cognitive disorder, anti-tumor, and anti-cardiovascular disease drugs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2026537458000001_ABST
    Figure 2026537458000001_ABST
Patent Text Reader

Abstract

This invention relates to the pharmaceutical field, and more specifically to crystalline forms A and B of 20(S)-protopanaxadiol, methods for preparing them, and their uses. Crystalline forms A and B provided in this invention differ in crystalline form from conventionally known 20(S)-protopanaxadiol, each having a distinct contour, being fully reproducible, exhibiting good bulk density, fluidity and stability, and good properties in the treatment of diseases such as antidepressants, anxiolytics, anticognitive disorders, Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), tumors or cardiovascular diseases, and are expected to have widespread use in the drug development of 20(S)-protopanaxadiol.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] [Cross-reference] This application claims the priority of Chinese Patent Application No. 2023114247117 filed on October 30, 2023, with the patent title being "Crystalline Form of 20(S)-Protopanaxadiol, Preparation Method and Use Thereof", the entire disclosure of which is incorporated herein by reference in its entirety. The present invention relates to the field of pharmaceuticals, and specifically relates to a crystalline form of 20(S)-Protopanaxadiol, a preparation method and use thereof.

Background Art

[0002] 20(S)-Protopanaxadiol, abbreviated as 20(S)-PPD, is a plant component with many pharmacological active functions including inhibiting proliferation of cancer cells, anti-depression, anti-anxiety, anti-cognitive impairment, prevention and / or treatment of Alzheimer's disease (AD) and amyotrophic lateral sclerosis (ALS), and anti-cardiovascular disease effects. Its molecular formula is C 30 H 52 O3, and its structural formula is as follows.

Chem.

[0003] At present, there are few studies on the crystalline form of 20(S)-Protopanaxadiol. The Chinese patent application with publication number CN115991729A discloses two crystalline forms of 20(S)-Protopanaxadiol, which are respectively prepared by heating and dissolving in acetone and acetonitrile, followed by cooling for crystallization.

[0004] Furthermore, several methods for preparing 20(S)-protopanaxadiol have been disclosed in previous studies. Many of these preparation methods use plant saponins (ginseng, Panax notoginseng, red ginseng, American ginseng, Gynostemma pentaphyllum) as raw materials, and obtain 20(S)-protopanaxadiol by techniques such as hydrolysis. Then, using alcohol as the main elution solvent, the product is separated and purified by column chromatography to finally obtain white powdered 20(S)-protopanaxadiol. However, the 20(S)-protopanaxadiol products obtained by the above methods (which contain amorphous crystals of 20(S)-protopanaxadiol) still have drawbacks such as low bulk density, low solubility, and poor mechanical stability.

[0005] In view of these circumstances, the present invention is provided. [Overview of the Initiative] [Problems that the invention aims to solve]

[0006] This invention provides a novel crystalline form of 20(S)-protopanaxadiol, a method for preparing it, and its use. [Means for solving the problem]

[0007] Specifically, it is as follows: In a first aspect, the present invention provides crystalline form A of 20(S)-protopanaxadiol. In the present invention, crystal form A exhibits characteristic diffraction peaks at at least 6.5°, 4.2°, and 15.7° in a powder X-ray diffraction pattern represented by a diffraction angle of 2θ±0.2°. Preferably, the crystal form A is further expressed in a powder X-ray diffraction pattern represented by a diffraction angle of 2θ ± 0.2°, (1) Exhibiting characteristic diffraction peaks at at least one location at 17.1°, 18.6°, and 13.1°, and / or (2) Characteristic diffraction peaks are observed at least one location at 17.9°, 10.6°, and 20.7°.

[0008] In a preferred embodiment, crystal form A exhibits characteristic diffraction peaks at at least 6.5°, 4.2°, 15.7°, 17.1°, 18.6°, 13.1°, 17.9°, 10.6°, and 20.7° in a powder X-ray diffraction pattern represented by a diffraction angle of 2θ ± 0.2°. In a more preferred embodiment, crystalline form A of 20(S)-protopanaxadiol described in the present invention basically has the powder X-ray diffraction pattern shown in Figure 1.

[0009] The crystal form A is represented by the position of the diffraction peak (Bragg angle 2θ, expressed in degrees), relative intensity (%), and lattice plane spacing d, and the data is basically as shown in Table 1. [Table 1]

[0010] In the present invention, the melting point of crystal form A is 219 to 221°C. Differential scanning calorimetry revealed that crystal form A showed an endothermic signal when heated to around 133°C, an exothermic signal when heated to around 175°C, and began to melt when heated to around 220°C. Its DSC curve is shown in Figure 2.

[0011] Crystal form A of 20(S)-protopanaxadiol provided by the present invention has a clear outline, is perfectly reproducible, has high bulk density and strong fluidity, exhibits excellent properties in particular, such as mechanical stability and solid stability, and shows higher solubility in FaSSIF (fasting artificial intestinal fluid), making it suitable for widespread use in the pharmaceutical development of 20(S)-protopanaxadiol.

[0012] In a second aspect, the present invention provides a method for preparing the crystalline form A. In the present invention, the method for preparing the crystalline form A includes dissolving a crude 20(S)-protopanaxadiol product in a good solvent to obtain a 20(S)-protopanaxadiol solution, adding a poor solvent dropwise to the 20(S)-protopanaxadiol solution until a gel-like substance is formed, and performing at least one temperature cycle on the gel-like substance. Herein, the crude 20(S)-protopanaxadiol product described in the present invention is a conventionally known compound and can be obtained from multiple routes.

[0013] In any embodiment of the present invention, the crude 20(S)-protopanaxadiol product may be selected from "protopanaxadiol" prepared by the preparation method described in the invention patent with publication number CN1252082C (Method for preparing protopanaxadiol and protopanaxatriol), or it may be selected from "crystal form A" described in the invention patent with publication number CN115991729A (crystal form A, crystal form B of 20(S)-protopanaxadiol and method for preparing them). As a result of identification and characterization, the crystal form of the above "protopanaxadiol" and "crystal form A" in CN115991729A is "crystal form D" described in the present invention (see "Comparative Examples and Test Examples" below in this specification).

[0014] In a more specific embodiment provided by the present invention, the crude 20(S)-protopanaxadiol product is preferably prepared by the method provided in Example 3 of the invention patent, publication number CN1252082C (Method for preparing protopanaxadiol and protopanaxatriol).

[0015] The method for preparing crystalline form A described in the present invention involves first dissolving the crude 20(S)-protopanaxadiol product in a good solvent to obtain a 20(S)-protopanaxadiol solution. Here, as the good solvent, a known solvent capable of favorably dissolving 20(S)-protopanaxadiol can be selected, which is preferably at least one selected from methyl isobutyl ketone, anisole and chloroform, and more preferably methyl isobutyl ketone.

[0016] To further control the dissolution state of the solute, the ratio of the used amounts of the crude 20(S)-protopanaxadiol product and the good solvent is preferably 10 to 30 mg : 0.5 to 1.0 mL, and more preferably 18 to 22 mg : 0.6 to 0.8 mL.

[0017] In the preparation method provided by the present invention, after obtaining the 20(S)-protopanaxadiol solution, it is preferable to further filter the 20(S)-protopanaxadiol solution using a filtration membrane with a pore size of 0.4 to 0.5 μm.

[0018] In the present invention, the above filtration operation can not only achieve conventional impurity removal, but also effectively eliminate the influence of impurities on the microstructure during crystal formation in the subsequent crystallization process via gas-liquid permeation, and further promote the smoother precipitation of crystal form A from the crude 20(S)-protopanaxadiol product solution.

[0019] The pore size of the filtration membrane described in the present invention is preferably 0.44 to 0.46 μm, and more preferably 0.45 μm.

[0020] The present invention does not particularly limit the material of the filtration membrane, which may be obtained via conventional commercial channels in the art.

[0021] In a more specific embodiment provided by the present invention, the filtration membrane is selected from polytetrafluoroethylene filtration membranes.

[0022] The preparation method provided by the present invention preferably involves stirring the obtained 20(S)-protopanaxadiol solution to obtain a clarified solution. Preferably, the stirring speed is 500 to 2000 r / min, and more preferably 1000 r / min.

[0023] Furthermore, the present invention involves adding a poor solvent dropwise to the 20(S)-protopanaxadiol solution before a gel-like substance is formed, and then subjecting the gel-like substance to at least one temperature cycle. Here, the poor solvent can be selected from any solvent unfavorable to 20(S)-protopanaxadiol, and is particularly preferably at least one selected from n-heptane, n-hexane, and n-pentane, with n-heptane being more preferable.

[0024] In the present invention, the ratio of the amount of poor solvent used to the amount of good solvent used is preferably 5 mL:0.5-1.0 mL, more preferably 5 mL:0.6-0.8 mL, in order to better promote crystal formation.

[0025] In the preparation method provided by the present invention, temperature control is one of the important factors for the formation of high-quality crystals, and the solubility of 20(S)-protopanaxadiol in the good and poor solvents described in the present invention is affected to some extent by temperature, and appropriate temperature control is advantageous for the growth and crystallization of 20(S)-protopanaxadiol. Preferably, the temperature cycle includes raising the temperature of the gel-like material to 45-55°C, maintaining a constant temperature for 1-3 hours, then lowering the temperature to 4-6°C at a rate of 0.05-1°C / min, and growing the crystals for 1-3 hours while maintaining a constant temperature. Here, it is preferable that the temperature is raised at a constant rate to 45-55°C over 10-40 minutes, and the cooling rate is preferably 0.1-0.5°C / min.

[0026] In a preferred embodiment provided by the present invention, the temperature cycle includes raising the temperature of the gel-like substance to 50°C over 0.3 to 0.5 hours, maintaining a constant temperature for 2 hours, and then lowering the temperature to 5°C at a rate of 0.1 to 0.5°C / min, while maintaining a constant temperature for 2 hours to grow the crystal.

[0027] The preparation method provided by the present invention preferably involves performing a temperature cycle on the gel-like substance while simultaneously stirring the gel-like substance in all stages except the constant-temperature crystal growth stage (i.e., the heating, constant temperature after heating to 45-55°C, and cooling stages are all performed under stirring), and the rotation speed of the stirring is preferably 800-1200 r / min, and more preferably 1000 r / min.

[0028] The present invention does not particularly limit the specific operation method of stirring in each step, and any of the conventional stirring operations in the art, such as magnetic stirring, may be used.

[0029] In the present invention, the number of temperature cycles is preferably 2 to 4. After the temperature cycle is completed, the precipitated solid crystal form A can be obtained.

[0030] In this invention, it is preferable to filter and dry the precipitated solid crystal form A, and the filtering and drying steps can be carried out using conventional methods in the art, and the present invention is not particularly limited.

[0031] In the optimal embodiment of the present invention, the preparation method preferably includes the following steps. Approximately 20 mass units of crude 20(S)-protopanaxadiol solid are weighed and placed in a glass vial. 0.6 volume units of methyl isobutyl ketone are added to dissolve the crude 20(S)-protopanaxadiol solid. The sample solution is filtered into a new glass bottle using a polytetrafluoroethylene filtration membrane with a pore size of 0.45 μm. A clarified solution is then obtained by magnetic stirring (rotation speed approximately 1000 r / min). Five volume units of n-heptane are added dropwise to obtain a gel-like sample. The sample is then transferred to temperature cycling conditions for crystal growth and crystallization.

[0032] In the preparation method described in the present invention, unless otherwise specified, when the unit of mass is mg, the corresponding unit of volume is mL.

[0033] The temperature cycling conditions are specifically as follows: First cycle: The temperature is raised to 50°C at a constant rate over 0.3 hours, maintained at 50°C for 2 hours, then cooled down to 5°C at a rate of 0.5°C / min, and maintained at 5°C for 2 hours. Second cycle: The temperature is raised to 50°C at a constant rate over 0.4 hours, maintained at 50°C for 2 hours, then cooled down to 5°C at a rate of 0.3°C / min, and maintained at 5°C for 2 hours. Third cycle: The temperature is raised to 50°C at a constant rate over 0.5 hours, maintained at 50°C for 2 hours, then cooled down to 5°C at a rate of 0.1°C / min, and maintained at 5°C for 2 hours. In the three cycles described above, all procedures are carried out under magnetic stirring, except for the crystal growth process which involves letting the crystals stand while maintaining a constant temperature of 5°C for 2 hours. After a total of three cycles, a solid precipitates, and the obtained solid is centrifuged to obtain crystal form A.

[0034] The preparation method provided by the present invention can perfectly reproduce crystalline form A of 20(S)-protopanaxadiol, and the product quality is stable and reliable, playing an important role in the subsequent development and application of crystalline form A of 20(S)-protopanaxadiol.

[0035] Figure 3 shows the powder X-ray diffraction pattern of the crude 20(S)-protopanaxadiol product prepared in Example 3 of the invention patent, publication number CN1252082C (Method for preparing protopanaxadiol and protopanaxatriol).

[0036] As can be seen from Figure 3, the crude 20(S)-protopanaxadiol product exhibits characteristic diffraction peaks at 5.0°, 5.8°, 12.6°, 17.5°, 7.3°, 17.0°, 10.0°, 16.6°, and 15.3° in the powder X-ray diffraction pattern represented by a diffraction angle of 2θ±0.2°.

[0037] The location of the diffraction peak (Bragg angle 2θ, expressed in degrees), relative intensity (%), and lattice plane spacing d represent the crude 20(S)-protopanaxadiol product shown in Figure 3, and the data is basically as shown in Table 2. [Table 2]

[0038] The crude 20(S)-protopanaxadiol product has a melting point of 215-217°C. Differential scanning calorimetry revealed that the crude 20(S)-protopanaxadiol product showed an endothermic signal when heated to around 50°C, an exothermic signal when heated to around 159°C, and began to melt when heated to around 216°C. Its DSC curve is shown in Figure 4.

[0039] The crude 20(S)-protopanaxadiol product can also be represented as crystal form D in this invention. As can be seen by comparing the information such as the powder X-ray diffraction pattern (i.e., Figure 3) and DSC curve (i.e., Figure 4) of the crude 20(S)-protopanaxadiol product (crystal form D) with the information such as the powder X-ray diffraction pattern (i.e., Figure 1) and DSC curve (i.e., Figure 2) of crystal form A of 20(S)-protopanaxadiol that this invention aims to protect, crystal form A obtained in this invention has a different crystal form from the conventionally known 20(S)-protopanaxadiol.

[0040] In a third aspect, the present invention provides another crystalline form B of 20(S)-protopanaxadiol.

[0041] In the present invention, crystal form B exhibits characteristic diffraction peaks at at least 7.5°, 14.4°, and 15.4° in a powder X-ray diffraction pattern represented by a diffraction angle of 2θ±0.2°. Preferably, the crystal form B is further represented in the powder X-ray diffraction pattern with a diffraction angle of 2θ ± 0.2°, (1) Exhibiting characteristic diffraction peaks at at least one location at 4.6°, 3.8°, and 16.9°, and / or (2) Characteristic diffraction peaks are observed at least one location at 18.1°, 6.7°, and 13.1°.

[0042] In a preferred embodiment, crystal form B exhibits characteristic diffraction peaks at at least 7.5°, 14.4°, 15.4°, 4.6°, 3.8°, 16.9°, 18.1°, 6.7°, and 13.1° in a powder X-ray diffraction pattern represented by a diffraction angle of 2θ±0.2°. In a more preferred embodiment, crystalline form B of 20(S)-protopanaxadiol described in the present invention basically has the powder X-ray diffraction pattern shown in Figure 5.

[0043] The crystal form B is represented by the position of the diffraction peak (Bragg angle 2θ, expressed in degrees), relative intensity (%), and lattice plane spacing d, and the data is basically as shown in Table 3. [Table 3]

[0044] In the present invention, the melting point of crystal form B is 218 to 220°C. Differential scanning calorimetry revealed that crystal form B began to melt when heated to around 219°C, and its DSC curve is shown in Figure 6.

[0045] The crystalline form B of 20(S)-protopanaxadiol provided by the present invention is characterized by a clear outline, complete reproducibility, high bulk density, strong fluidity, and good solid stability.

[0046] In a fourth aspect, the present invention provides a method for preparing the crystalline form B. In the present invention, the method for preparing crystalline form B includes first raising the temperature of the crude 20(S)-protopanaxadiol product to 160-180°C, holding it for 2-5 minutes, and then lowering the temperature to 25-35°C to obtain crystalline form B. Here, the crude 20(S)-protopanaxadiol product is similarly a conventionally known compound (crystalline form D), and in a more specific embodiment provided by the present invention, the crude 20(S)-protopanaxadiol product is prepared by the method provided in Example 3 of the invention patent, publication number CN1252082C (Method for preparing protopanaxadiol and protopanaxatriol).

[0047] In the method for preparing crystalline form B described in the present invention, the heating is preferably carried out in an inert gas atmosphere. Here, the inert gas is preferably N2.

[0048] In the present invention, the rate of heating is preferably 8 to 15°C / min, and more preferably 10 to 12°C / min. The rate of cooling is preferably 25 to 35°C / min, and more preferably 30°C / min.

[0049] In the optimal embodiment of the present invention, the preparation method preferably includes the following steps. The crude 20(S)-protopanaxadiol solid is placed in a DSC aluminum pan and heated to 170°C at a heating rate of 10-15°C / min under nitrogen purging conditions. After maintaining a constant temperature for 3 minutes, the temperature is cooled to 30°C at a cooling rate of 30°C / min, and the solid is collected.

[0050] As can be seen by comparing the information such as the powder X-ray diffraction pattern (i.e., Figure 3) and DSC curve (i.e., Figure 4) of the crude 20(S)-protopanaxadiol with the information such as the powder X-ray diffraction pattern (i.e., Figure 5) and DSC diagram (i.e., Figure 6) of crystalline form B of 20(S)-protopanaxadiol that the present invention aims to protect, crystalline form B obtained in the present invention has a different crystalline form from conventionally known 20(S)-protopanaxadiol.

[0051] In a fifth aspect, the present invention further provides a pharmaceutical composition containing crystalline form A or crystalline form B of 20(S)-protopanaxadiol, which specifically includes, but is not limited to, sterile powder injections, tablets, capsules, microspheres, self-emulsifying compositions, dry suspensions, lyophilized powders, or infusions.

[0052] The composition described in the present invention may further contain pharmaceutically acceptable auxiliary materials, more preferably the pharmaceutically acceptable auxiliary material comprising at least one of a carrier, a diluent, and an excipient. For example, if the composition is a freeze-dried powder, the pharmaceutically acceptable auxiliary material may be an excipient, and if the composition is a tablet, the pharmaceutically acceptable auxiliary material may be a disintegrant, an excipient, etc.

[0053] Crystalline form A or crystalline form B of 20(S)-protopanaxadiol described in the present invention has the same chemical formula structure as crude 20(S)-protopanaxadiol (only the crystal form differs) and similarly exhibits ideal therapeutic effects in antidepressant, anti-anxiety, anti-cognitive disorder, prevention and / or treatment of Alzheimer's disease (AD) and amyotrophic lateral sclerosis (ALS), as well as antitumor or anti-cardiovascular disease.

[0054] Since the crystalline form A or crystalline form B of 20(S)-protopanaxadiol obtained in the present invention has ideal physicochemical properties, those skilled in the art can predict that even after preparing them into various pharmaceutical formulations, the stability and therapeutic effect of the said pharmaceutical formulations can be further improved, and the determination of specific dosage forms and formulations is already known to those skilled in the art.

[0055] Furthermore, the present invention further protects the use of either crystalline form A or crystalline form B of the above-mentioned 20(S)-protopanaxadiol. (1) Use in the preparation of antidepressant, anti-anxiety, anti-cognitive disorder, anti-tumor, or anti-cardiovascular disease drugs. (2) Use for antidepressant, anti-anxiety, anti-cognitive disorder, anti-tumor or anti-cardiovascular disease, (3) Use in the preparation of pharmaceuticals for the prevention and / or treatment of Alzheimer's disease (AD) and amyotrophic lateral sclerosis (ALS).

[0056] Crystallized forms A or B of 20(S)-protopanaxadiol described in the present invention exhibit excellent medicinal activity in areas such as antidepressant, anxiolytic, anticognitive disorder, antitumor, and anticardiovascular disease, as well as in the prevention and / or treatment of Alzheimer's disease (AD) and amyotrophic lateral sclerosis (ALS). Furthermore, crystallized forms A or B of 20(S)-protopanaxadiol described in the present invention exhibit superior bulk density, fluidity, and stability compared to crude 20(S)-protopanaxadiol, offering advantages in the pharmaceutical development of 20(S)-protopanaxadiol. [Effects of the Invention]

[0057] beneficial effects This invention provides novel crystalline forms A and B of 20(S)-protopanaxadiol, and further provides corresponding preparation methods and uses. The novel crystalline forms provided by this invention have a clear outline, are fully reproducible, and exhibit good properties in bulk density, flowability, and stability, and are expected to have widespread use in the pharmaceutical development of 20(S)-protopanaxadiol. The preparation methods provided by this invention are simple to operate and easy to perform, making them advantageous for dissemination and application. [Brief explanation of the drawing]

[0058] [Figure 1] This is the powder X-ray diffraction pattern of crystalline form A of 20(S)-protopanaxadiol in the present invention. [Figure 2]This is the differential scanning calorimetry curve of crystalline form A of 20(S)-protopanaxadiol in the present invention. [Figure 3] This is the powder X-ray diffraction pattern of the crude 20(S)-protopanaxadiol product (crystal form D) used in the present invention. [Figure 4] This is a differential scanning calorimetry curve of the crude 20(S)-protopanaxadiol product (crystal form D) used in the present invention. [Figure 5] This is the powder X-ray diffraction pattern of crystalline form B of 20(S)-protopanaxadiol in the present invention. [Figure 6] This is the differential scanning calorimetry curve of crystalline form B of 20(S)-protopanaxadiol in the present invention. [Figure 7] This is a dynamic water adsorption diagram of crystalline form A of 20(S)-protopanaxadiol in the present invention. [Figure 8] This is a dynamic water adsorption diagram of crystalline form B of 20(S)-protopanaxadiol in the present invention. [Figure 9] This is a dynamic water adsorption diagram of the crude 20(S)-protopanaxadiol product (crystalline form D) used in the present invention. [Figure 10] This is a PLM photograph of crystalline form A of 20(S)-protopanaxadiol in the present invention. [Figure 11] This is a PLM photograph of crystalline form B of 20(S)-protopanaxadiol in the present invention. [Figure 12] This is a PLM photograph of the crude 20(S)-protopanaxadiol product (crystalline form D) used in the present invention. [Modes for carrying out the invention]

[0059] The present invention will be further described below with reference to specific examples. It should be understood that these examples are merely illustrative and do not limit the scope of the present invention. It is clear that the examples described represent only a portion of the present invention, not all examples. All other examples that a person skilled in the art could obtain without performing the work of inventive step based on the examples of the present invention are all within the scope of the present invention.

[0060] The abbreviations used in this invention are explained below. XRPD: Powder X-ray diffraction DSC: Differential Scanning Calorimetry TGA: Thermogravimetric analysis DVS: Dynamic Moisture Adsorption

[0061] The powder X-ray diffraction patterns described in this invention are collected using a PANalytical Empyrean or X'Pert3 powder X-ray diffractometer. The method parameters for powder X-ray diffraction described in this invention are as follows: X-ray source: Cu, Kα Kα1(Å):1.54060;Kα2(Å):1.54439 Kα2 / Kα1 intensity ratio: 0.50 Voltage: 45kV Current: 40mA Scan range: 3.0 to 40.0 degrees

[0062] The differential scanning calorimetry (DSC) curves described in this invention are acquired using a TA Discovery 2500. The method parameters for differential scanning calorimetry (DSC) described in this invention are as follows: Scanning speed: 10°C / min Protective gas: N2

[0063] The thermogravimetric analysis (TGA) curves described in this invention are acquired using a TA Discovery 5500. The method parameters for the thermogravimetric analysis (TGA) described in this invention are as follows: Scanning speed: 10°C / min Protective gas: N2

[0064] In this invention, high-performance liquid chromatography (HPLC) purity data is obtained from a Thermo Fisher Vanquish Core, and the detector used is a diode array detector (DAD). The method parameters for HPLC to measure purity as described in this invention are as follows: 1. Column: Xselect CSH C18, 150×4.6mm, 3.5μm 2, Mobile phase: A: Water B: Acetonitrile The dissolution gradient is as follows: [Table 4] 3, Flow rate: 1.0mL / min 4. Sample introduction volume: 5 μL 5. Detection wavelength: 203nm 6. Column temperature: 40℃ 7. Temperature of the sample introduction device: Room temperature 8. Diluent: Acetonitrile

[0065] Unless otherwise specified, the following examples are all performed under room temperature conditions.

[0066] Example 1 Preparation of crude 20(S)-protopanaxadiol product: Crude 20(S)-protopanaxadiol was prepared using the method of Example 3 of the invention patent application number 200410018038.8 (Method for preparing protopanaxadiol and protopanaxatriol). Figure 3 shows the powder X-ray diffraction pattern of the crude 20(S)-protopanaxadiol product using Cu-Kα radiation. The location of the diffraction peak (Bragg angle 2θ, expressed in degrees), relative intensity (%), and lattice plane spacing d represent the crude 20(S)-protopanaxadiol product shown in Figure 3, and the data are shown in Table 2. Differential scanning calorimetry revealed that the crude 20(S)-protopanaxadiol product showed an endothermic signal when heated to around 50°C, an exothermic signal when heated to around 159°C, and began to melt when heated to around 216°C. Its DSC curve is shown in Figure 4.

[0067] Example 2 Preparation of crystalline form A of 20(S)-protopanaxadiol: Using the crude 20(S)-protopanaxadiol prepared in Example 1 as a raw material, approximately 20 mg of the crude 20(S)-protopanaxadiol solid was weighed and placed in a 20 mL glass vial. 0.6 mL of methyl isobutyl ketone was added to dissolve the crude 20(S)-protopanaxadiol solid. The sample solution was filtered into a new 20 mL glass vial using a polytetrafluoroethylene filtration membrane with a pore size of 0.45 μm, and then magnetically stirred (rotation speed approximately 1000 r / min) to obtain a clarified solution. 5 mL of n-heptane was added dropwise to obtain a gel-like sample, and the sample was transferred to temperature cycling conditions for crystal growth (all stages except the constant temperature growth stage were performed under magnetic stirring, with a magnetic stirring rotation speed of approximately 1000 r / min).

[0068] The temperature cycling conditions are as follows: First cycle: The temperature is raised to 50°C at a constant rate over 0.3 hours, maintained at 50°C for 2 hours, then cooled down to 5°C at a rate of 0.5°C / min, and maintained at 5°C for 2 hours. Second cycle: The temperature is raised to 50°C at a constant rate over 0.4 hours, maintained at 50°C for 2 hours, then cooled down to 5°C at a rate of 0.3°C / min, and maintained at 5°C for 2 hours. Third cycle: The temperature is raised to 50°C at a constant rate over 0.5 hours, maintained at 50°C for 2 hours, then cooled down to 5°C at a rate of 0.1°C / min, and maintained at 5°C for 2 hours. After a total of three cycles, a solid precipitated, and the obtained solid was centrifuged to obtain crystal form A.

[0069] Figure 1 shows the powder X-ray diffraction pattern of crystalline form A of the 20(S)-protopanaxadiol using Cu-Kα radiation. The crystal form A of the 20(S)-protopanaxadiol is represented by the position of the diffraction peak (Bragg angle 2θ, expressed in degrees), relative intensity (%), and lattice plane spacing d, and the data is shown in Table 1.

[0070] Differential scanning calorimetry revealed that crystal form A showed an endothermic signal when heated to around 133°C, an exothermic signal when heated to around 175°C, and began to melt when heated to around 220°C. Its DSC diagram is shown in Figure 2.

[0071] Example 3 Preparation of crystalline form A of 20(S)-protopanaxadiol: Using the crude 20(S)-protopanaxadiol prepared in Example 1 as a raw material, approximately 19.8 mg of the crude 20(S)-protopanaxadiol solid was weighed and placed in a 20 mL glass vial. 0.8 mL of anisole was added to dissolve the crude 20(S)-protopanaxadiol solid. The sample solution was filtered into a new 20 mL glass vial using a polytetrafluoroethylene filtration membrane with a pore size of 0.45 μm, and then magnetically stirred (rotation speed approximately 1000 r / min) to obtain a clarified solution. 5 mL of n-pentane was added dropwise to obtain a gel-like sample, and the sample was transferred to temperature cycling conditions for crystal growth (all stages except the constant temperature crystal growth stage were performed under magnetic stirring, with a rotation speed of approximately 1000 r / min).

[0072] The temperature cycling procedure is as follows: First cycle: The temperature is raised to 50°C at a constant rate over 0.3 hours, maintained at 50°C for 2.5 hours, then cooled down to 5°C at a rate of 0.5°C / min, and maintained at 5°C for 2.5 hours. Second cycle: The temperature is raised to 50°C at a constant rate over 0.4 hours, maintained at 50°C for 2.5 hours, then cooled down to 5°C at a rate of 0.3°C / min, and maintained at 5°C for 2 hours. Third cycle: The temperature is raised to 50°C at a constant rate over 0.5 hours, maintained at 50°C for 2.5 hours, then cooled down to 5°C at a rate of 0.1°C / min, and maintained at 5°C for 2.5 hours. After a total of three cycles, a solid precipitated, and when the solid crystal obtained by centrifugation was detected, it was found to be crystal form A.

[0073] Example 4 Preparation of crystalline form A of 20(S)-protopanaxadiol: Using the crude 20(S)-protopanaxadiol prepared in Example 1 as a raw material, approximately 19.8 mg of the crude 20(S)-protopanaxadiol solid was weighed and placed in a 20 mL glass vial. 0.8 mL of chloroform was added to dissolve the crude 20(S)-protopanaxadiol solid. The sample solution was filtered into a new 20 mL glass vial using a polytetrafluoroethylene filtration membrane with a pore size of 0.45 μm, and then magnetically stirred (rotation speed approximately 1000 r / min) to obtain a clarified solution. 5 mL of n-hexane was added dropwise to obtain a gel-like sample, and the sample was transferred to temperature cycling conditions for crystal growth (all stages except the constant temperature crystal growth stage were performed under magnetic stirring, with a rotation speed of approximately 1000 r / min).

[0074] The temperature cycling procedure is as follows: First cycle: The temperature is raised to 50°C at a constant rate over 0.3 hours, maintained at 50°C for 1.5 hours, then cooled down to 5°C at a rate of 0.5°C / min, and maintained at 5°C for 1.5 hours. Second cycle: The temperature is raised to 50°C at a constant rate over 0.4 hours, maintained at 50°C for 1.5 hours, then cooled down to 5°C at a rate of 0.3°C / min, and maintained at 5°C for 1.5 hours. Third cycle: The temperature is raised to 50°C at a constant rate over 0.5 hours, maintained at 50°C for 1.5 hours, then cooled down to 5°C at a rate of 0.1°C / min, and maintained at 5°C for 1.5 hours. After a total of three cycles, a solid precipitated, and when the solid crystal obtained by centrifugation was detected, it was found to be crystal form A.

[0075] Example 5 Preparation of crystalline form B of 20(S)-protopanaxadiol: Using the crude 20(S)-protopanaxadiol prepared in Example 1 as the raw material, approximately 15 mg of the crude 20(S)-protopanaxadiol solid was weighed and placed in a DSC aluminum pan. Under nitrogen purging conditions, the temperature was raised to 170°C at a heating rate of 10°C / min, maintained at a constant temperature for 3 minutes, and then cooled to 30°C at a cooling rate of 30°C / min. A total of 17 batches were set up in parallel. All solids were collected and designated as crystalline form B.

[0076] The powder X-ray diffraction pattern of crystalline form B of the 20(S)-protopanaxadiol, obtained using Cu-Kα radiation, is shown in Figure 5. The crystal form B of the 20(S)-protopanaxadiol is represented by the position of the diffraction peak (Bragg angle 2θ, expressed in degrees), relative intensity (%), and lattice plane spacing d, and the data is shown in Table 3.

[0077] Differential scanning calorimetry revealed that crystal form B began to melt when heated to around 219°C, and its DSC curve is shown in Figure 6.

[0078] Comparative Example 1 Using the crude 20(S)-protopanaxadiol prepared in Example 1 as a starting material, 19.7 mg of the crude 20(S)-protopanaxadiol was weighed and placed in a 2 mL glass vial. 0.3 mL of tetrahydrofuran / n-heptane (volume ratio 1:1) was added to obtain a suspension. This suspension was magnetically stirred at 50°C for about 2 hours (rotation speed about 1000 r / min), then sealed. The temperature was then lowered from 50°C to 5°C at a rate of 0.1°C / min, and then allowed to stand at 5°C for about 1 day to obtain solid crystals. Upon detection, the solid crystals produced in this comparative example were of crystal form D.

[0079] Comparative Example 2 Using the crude 20(S)-protopanaxadiol prepared in Example 1 as a raw material, 20.1 mg of the crude 20(S)-protopanaxadiol solid was weighed and placed in a 3 mL glass vial, and 1.0 mL of acetonitrile was added to obtain a suspension. This suspension was magnetically stirred (rotation speed approximately 1000 r / min) at 50°C for about 2 hours, then sealed, and the temperature was lowered from 50°C to 5°C at a rate of 0.1°C / min. After that, it was left to stand at a constant temperature of 5°C for about 1 day to obtain solid crystals. Upon detection, the solid crystals produced in this comparative example were of crystal form D.

[0080] Comparative Example 3-6: Using the crude 20(S)-protopanaxadiol prepared in Example 1 as a starting material, approximately 20 mg of the crude 20(S)-protopanaxadiol solid was weighed and placed in a 3 mL glass vial. The corresponding volume of solvent was added, the 3 mL glass vial was sealed with Parafilm, four small holes were made in the Parafilm, and the mixture was allowed to evaporate at room temperature until the solid precipitated.

[0081] The detailed test conditions for each of the above comparative examples are shown in Table 4. [Table 5] Upon detection, all solid crystals produced in Comparative Example 3-6 were found to be of crystal form D.

[0082] Comparative Example 7 Using the crude 20(S)-protopanaxadiol prepared in Example 1 as a raw material, approximately 20 mg of the crude 20(S)-protopanaxadiol solid was weighed and placed in a 20 mL glass vial. 0.6 mL of methyl isobutyl ketone was added to dissolve the crude 20(S)-protopanaxadiol solid. Subsequently, magnetic stirring (rotation speed approximately 1000 r / min) was performed to obtain a clarified solution. The solvent was allowed to evaporate slowly and naturally, allowing the solid to precipitate. The solid obtained by centrifugation was detected, and the solid crystals produced in this comparative example were of crystal form D.

[0083] Test Example 1: Hygroscopicity Test In this test example, the crude 20(S)-protopanaxadiol product (crystalline form D) prepared in Example 1, crystalline form A of 20(S)-protopanaxadiol prepared in Example 2, and crystalline form B of 20(S)-protopanaxadiol prepared in Example 5 were used as test samples, and the hygroscopicity of each test sample was measured.

[0084] The dynamic water absorption / desorption (DVS) curves for each sample were measured and prepared, and the experimental results are shown in Table 5. Here, the DVS curve for crystal form A described in Example 2 is shown in Figure 7, the DVS curve for crystal form B described in Example 5 is shown in Figure 8, and the DVS curve for the crude 20(S)-protopanaxadiol product described in Example 1 is shown in Figure 9. [Table 6]

[0085] According to the definition of hygroscopicity of pharmaceuticals in the "Chinese Pharmacopoeia 2020 Edition," the crystalline form A, crystalline form B, and 20(S)-protopanaxadiol crude products described in the present invention are all slightly hygroscopic, can maintain stability even under high humidity conditions, can maintain stability during production, storage, and use without requiring specific humidity control conditions, and can well meet the requirements for the production and use of pharmaceuticals. The following describes the hygroscopic characteristics and the definition of weight increase due to moisture absorption (Guiding Principles for Hygroscopic Testing of Pharmaceuticals in the Chinese Pharmacopoeia 2020 Edition). Deliquescence: Absorbs sufficient moisture to form a liquid. Highly hygroscopic: Weight increase due to moisture absorption is 15% or more. Hygroscopic: Weight increase due to moisture absorption is less than 15% but more than 2%. Slightly hygroscopic: Weight increase due to moisture absorption is less than 2% but 0.2% or more. No or minimal hygroscopicity: Weight increase due to moisture absorption is less than 0.2%.

[0086] Test Example 2: Solubility Test In this test example, the crude 20(S)-protopanaxadiol product (crystal form D) prepared in Example 1, the crystal form A of 20(S)-protopanaxadiol prepared in Example 2, and the crystal form B of 20(S)-protopanaxadiol prepared in Example 5 were used as test samples, and the solubility of each test sample was measured. 50 mg of each test sample was weighed, and suspensions were prepared using 5.0 mL of pure water, pH 1 buffer, SGF (artificial gastric fluid), FaSSIF (fasting artificial intestinal fluid), and FeSSIF (feeding artificial intestinal fluid). These suspensions were then equilibrated at 37°C for 1, 2, 4, and 24 hours, after which the solutions were filtered to obtain clarified solutions. The sample content in the saturated solutions was measured by HPLC. The test results are shown in Table 6.

[0087] The test results showed that the 24-hour solubility of crystalline form A, crystalline form B, and crude 20(S)-protopanaxadiol was low in media such as pure water and pH 1 buffer. The 24-hour solubility of crystalline form A was 0.13-0.15 μg / mL, and the solubility of crystalline forms B and D was less than LOQ. In SGF, there was no significant difference in the solubility of crystalline form A, crystalline form B, and crude 20(S)-protopanaxadiol (crystalline form D), and in FaSSIF, the solubility of crystalline form A and crude 20(S)-protopanaxadiol (crystalline form D) was higher than that of crystalline form B. [Table 7]

[0088] Test Example 3: Bulk Density and Tap Density Test In this test example, the crude 20(S)-protopanaxadiol product (crystal form D) prepared in Example 1, the crystal form A of 20(S)-protopanaxadiol prepared in Example 2, and the crystal form B of 20(S)-protopanaxadiol prepared in Example 5 were used as test samples, and the bulk density and tap density of each test sample were measured.

[0089] Approximately 800 mg of each test sample was taken and placed in a 5 mL graduated cylinder, and the volume was recorded. The graduated cylinder was then lightly tapped 200 times on a table surface, and the volume was recorded. This test was performed three times in parallel. The test results are shown in Table 7. [Table 8]

[0090] Test Example 4: Angle of Repose Test In this test example, the crude 20(S)-protopanaxadiol product (crystal form D) prepared in Example 1, the crystal form A of 20(S)-protopanaxadiol prepared in Example 2, and the crystal form B of 20(S)-protopanaxadiol prepared in Example 5 were used as test samples, and the angle of repose of each test sample was measured.

[0091] Appropriate amounts of each test sample were collected. A funnel was fixed to an iron stand and positioned perpendicular to the table surface. The collected samples of crystal form A and crystal form B were placed in the funnel and allowed to free-fall to form cone bodies. The height and diameter of the cone bodies were then measured, and the angle of repose was calculated. This test was performed three times in parallel. The test results are shown in Table 8. As a result, crystal form A had a smaller angle of repose and showed better fluidity than crystal form B and the crude 20(S)-protopanaxadiol product. [Table 9]

[0092] Test Example 5: Contact Angle Test In this test example, the crude 20(S)-protopanaxadiol product (crystal form D) prepared in Example 1, crystal form A of 20(S)-protopanaxadiol prepared in Example 2, and crystal form B of 20(S)-protopanaxadiol prepared in Example 5 were used as test samples, and the contact angle of each test sample was measured.

[0093] Appropriate amounts of each test sample were taken, and the contact angle with water was measured. This test was performed twice in parallel. The test results are shown in Table 9. [Table 10]

[0094] Test Example 6: Mechanical Stability Test In this test example, the crude 20(S)-protopanaxadiol product (crystal form D) prepared in Example 1, crystal form A of 20(S)-protopanaxadiol prepared in Example 2, and crystal form B of 20(S)-protopanaxadiol prepared in Example 5 were used as test samples, and the mechanical stability of each test sample was measured. Appropriate amounts of each test sample were taken, placed in an agate mortar, and manually ground for approximately 3 minutes before measuring the crystal form. The results showed that crystal form A, crystal form B, and the crude 20(S)-protopanaxadiol all transformed into a nearly amorphous state after grinding. Appropriate amounts of each test sample were taken, placed in a tablet press, and compressed at a pressure of 200 MPa. After compression, the crystal form was measured. The test results showed that crystal form A, crystal form B, and the 20(S)-protopanaxadiol crude product did not undergo crystal form transition after tableting. However, the crystallinity of both crystal form B and the 20(S)-protopanaxadiol crude product decreased, indicating that crystal form A was superior to crystal form B and the 20(S)-protopanaxadiol crude product.

[0095] Test Example 7: Thermodynamic Stability Test In this test example, the crude 20(S)-protopanaxadiol product (crystal form D) prepared in Example 1, the crystal form A of 20(S)-protopanaxadiol prepared in Example 2, and the crystal form B of 20(S)-protopanaxadiol prepared in Example 5 were used as test samples, and the thermodynamic stability of each test sample was measured.

[0096] An appropriate amount of crystalline form A was placed in a 2 mL glass vial, 0.5 mL of the corresponding solvent was added, and the mixture was magnetically stirred at the corresponding temperature for approximately 5 hours to obtain a suspension. Each suspension was then filtered into a new 2 mL glass vial using a polytetrafluoroethylene filter with a pore size of 0.45 μm at room temperature or 50 °C. Approximately 5 mg each of crystalline form A, crystalline form B, and crude 20(S)-protopanaxadiol was weighed and added to the filtrate after filtration, and the mixture was magnetically stirred at the corresponding temperature. The test results showed that crystalline form A was obtained after stirring the mixture of crystalline form A, crystalline form B, and crude 20(S)-protopanaxadiol at room temperature and 50 °C, and the test results are shown in Table 10. The test results showed that crystalline form A was more stable than crystalline form B and crude 20(S)-protopanaxadiol within the temperature range from room temperature to 50 °C. [Table 11]

[0097] Test Example 8: Solid Stability Test In this test example, the crude 20(S)-protopanaxadiol product (crystal form D) prepared in Example 1, crystal form A of 20(S)-protopanaxadiol prepared in Example 2, and crystal form B of 20(S)-protopanaxadiol prepared in Example 5 were used as test samples, and the solid stability of each test sample was measured.

[0098] Each test sample was weighed to an appropriate volume and left in a sealed state at 80°C for 1 day. Stability tests were then performed by leaving the samples open at 25°C / 60%RH and 40°C / 75%RH for 1 month. The physical stability of the solid samples separated under different conditions was evaluated by measuring the crystal form using XRPD, and the chemical stability was evaluated by measuring the chemical purity using HPLC. The evaluation results are summarized in Table 11. Based on the XRPD results, crystal form A, crystal form B, and the crude 20(S)-protopanaxadiol did not undergo crystal form transition under any of the three conditions. HPLC results showed that the crude 20(S)-protopanaxadiol product showed a slight decrease in purity after being left at 80°C in a sealed state for 1 day, and a slight decrease in chemical purity after being left at 25°C / 60%RH and 40°C / 75%RH in an open state for 1 month. Crystal forms A and B did not show a significant decrease in chemical purity under any of the three conditions, indicating that crystal forms A and B have better solid stability. [Table 12]

[0099] Test Example 9: Polarizing Microscope (PLM) Test In this test example, crude 20(S)-protopanaxadiol (crystal form D) prepared in Example 1, crystal form A of 20(S)-protopanaxadiol prepared in Example 2, and crystal form B of 20(S)-protopanaxadiol prepared in Example 5 were used as test samples, and PLM observation was performed on each test sample.

[0100] Figure 10 shows a PLM photograph of crystal form A described in Example 2, Figure 11 shows a PLM photograph of crystal form B described in Example 5, and Figure 12 shows a PLM photograph of the crude 20(S)-protopanaxadiol product described in Example 1. As can be seen from Figures 10, 11, and 12, observation with a polarizing microscope reveals that crystal forms A and B consist mainly of irregular particulate crystals, while crystal form D consists mainly of irregular particulate and needle-shaped / elongated crystals. As described above in detail through general descriptions and specific embodiments, it will be apparent to those skilled in the art that several modifications and improvements can be made based on the present invention. Therefore, any such modifications and improvements made without departing from the spirit of the present invention fall within the scope of protection of the present invention. [Industrial applicability]

[0101] This invention provides crystalline forms A and B of 20(S)-protopanaxadiol, methods for preparing them, and their uses. Crystalline forms A and B provided in this invention differ in crystalline form from conventionally known 20(S)-protopanaxadiol, each having a distinct contour, being fully reproducible, exhibiting good bulk density, fluidity, and stability, as well as favorable properties in the treatment of diseases such as antidepressants, anxiolytics, anticognitive disorders, antitumors, or anticardiovascular diseases, and thus have good economic value and application prospects in the pharmaceutical development of 20(S)-protopanaxadiol.

Claims

1. Crystal form A of 20(S)-protopanaxadiol, The aforementioned crystal form A exhibits characteristic diffraction peaks at at least 6.5°, 4.2°, and 15.7° in a powder X-ray diffraction pattern represented by a diffraction angle of 2θ ± 0.2°. Preferably, in a powder X-ray diffraction pattern where the crystal form A is represented by a diffraction angle of 2θ ± 0.2°, further, (1) It exhibits characteristic diffraction peaks at at least one location at 17.1°, 18.6°, and 13.1°, and / or (2) It shows characteristic diffraction peaks at at least one location at 17.9°, 10.6°, and 20.7°. More preferably, the crystal form A exhibits characteristic diffraction peaks at at least 6.5°, 4.2°, 15.7°, 17.1°, 18.6°, 13.1°, 17.9°, 10.6°, and 20.7° in a powder X-ray diffraction pattern represented by a diffraction angle of 2θ ± 0.2°. Crystal form A of 20(S)-protopanaxadiol, characterized by the above.

2. The crystalline form A of 20(S)-protopanaxadiol according to claim 1, characterized in that the melting point of the crystalline form A is 219 to 221°C.

3. A crude 20(S)-protopanaxadiol product is dissolved in a good solvent to obtain a 20(S)-protopanaxadiol solution, and a poor solvent is added dropwise to the 20(S)-protopanaxadiol solution until a gel-like substance is formed, and the gel-like substance is subjected to at least one temperature cycle. The temperature cycle includes raising the temperature of the gel-like substance to 45-55°C, maintaining a constant temperature for 1-3 hours, then lowering the temperature to 4-6°C at a rate of 0.05-1°C / min, and growing the crystals for 1-3 hours while maintaining a constant temperature. Preferably, the number of cycles in the temperature cycle is 2 to 4. A method for preparing crystalline form A of 20(S)-protopanaxadiol according to claim 1 or 2, characterized in that

4. The preparation method according to claim 3, characterized in that, before adding the poor solvent dropwise, the 20(S)-protopanaxadiol solution is filtered using a filtration membrane with a pore size of 0.4 to 0.5 μm, and / or the good solvent is at least one selected from methyl isobutyl ketone, anisole, and chloroform, and the poor solvent is at least one selected from n-heptane, n-hexane, and n-pentane.

5. Crystal form B of 20(S)-protopanaxadiol The aforementioned crystal form B exhibits characteristic diffraction peaks at at least 7.5°, 14.4°, and 15.4° in a powder X-ray diffraction pattern represented by a diffraction angle of 2θ ± 0.2°. Preferably, the crystal form B is represented in a powder X-ray diffraction pattern with a diffraction angle of 2θ ± 0.2°, and further, (1) It exhibits characteristic diffraction peaks at at least one location at 4.6°, 3.8°, and 16.9°, and / or (2) It shows characteristic diffraction peaks at at least one location at 18.1°, 6.7°, and 13.1°. More preferably, the crystal form B exhibits characteristic diffraction peaks at at least 7.5°, 14.4°, 15.4°, 4.6°, 3.8°, 16.9°, 18.1°, 6.7°, and 13.1° in a powder X-ray diffraction pattern represented by a diffraction angle of 2θ ± 0.2°. Crystalline form B of 20(S)-protopanaxadiol, characterized by the above.

6. Crystal form B of 20(S)-protopanaxadiol according to claim 5, characterized in that the XRPD data of crystal form B is basically as shown in Table 3, and / or the XRPD pattern of crystal form B is basically as shown in Figure 5.

7. The crystalline form B of 20(S)-protopanaxadiol according to claim 5 or 6, characterized in that the melting point of the crystalline form B is 218 to 220°C.

8. First, the crude 20(S)-protopanaxadiol is heated to 160-180°C and held for 2-5 minutes, then cooled to 25-35°C to obtain crystalline form B. Preferably, the rate of heating is 8 to 15°C / min, and / or the rate of cooling is 25 to 35°C / min. A method for preparing crystalline form B of 20(S)-protopanaxadiol according to any one of claims 5 to 7, characterized in that

9. A pharmaceutical composition, A therapeutically effective amount comprising crystal form A as described in any one of claims 1 to 2 or crystal form B as described in any one of claims 5 to 7, Preferably, the pharmaceutical composition further comprises pharmaceutically acceptable auxiliary materials. A pharmaceutical composition characterized by the following features.

10. Use of any of the following: crystalline form A according to any one of claims 1 to 2, crystalline form B according to any one of claims 5 to 7, or the pharmaceutical composition according to claim 9. (1) Use in the preparation of antidepressant, anti-anxiety, anti-cognitive disorder, anti-tumor, or anti-cardiovascular disease drugs, (2) Use for antidepressant, anti-anxiety, anti-cognitive disorder, anti-tumor or anti-cardiovascular disease, (3) Use in the preparation of pharmaceuticals for the prevention and / or treatment of Alzheimer's disease (AD) and amyotrophic lateral sclerosis (ALS).